Latest Tyrosine kinase Stories
SAN DIEGO, May 13, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc.
LONDON, May 13, 2015 /PRNewswire/ -- INTRODUCTIONOver decades, the oncology market has been led by surgery, chemotherapy and radiotherapy.
DUBLIN, May 13, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/42hpkb/nontyrosine) has announced the addition of the "Non-Tyrosine
New Studies Identify Molecular Target, Mitochondria-Specific Effects of ME-344; Results from First-in-Human Clinical Study Published in Cancer SAN DIEGO, May 4, 2015 /PRNewswire/ --
- On track to file INDs for BLU-285 and initiate clinical studies in mid-2015 - CAMBRIDGE, Mass., April 19, 2015 /PRNewswire/ -- Blueprint Medicines today announced new preclinical data demonstrating
DUBLIN, April 14, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/vktrnv/tyrosine_kinase) has announced the addition of the "Tyrosine
CAMBRIDGE, Mass., April 8, 2015 /PRNewswire/ -- Blueprint Medicines today announced it will present new preclinical data on its drug candidate BLU-285 in gastrointestinal stromal tumors (GIST), as
A study published in The Oncologist on February 26, 2015, challenges the role of fluorescence in situ hybridization (FISH) testing as the current gold standard for detecting EML4-ALK rearrangements
Research Presented at 2015 Gastrointestinal Cancers Symposium Highlights Clinical Utility of Caris Molecular Intelligence IRVING, Texas, Jan.
Study Seeks to Confirm a High Response Rate among Cancer Patients with MET and Axl Genetic Alterations SAN DIEGO, Dec. 23, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
- A hairdresser.